Immunocytokines Market by Indication, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030
The global immunocytokines market is expected to reach USD 5.3 billion in 2030 and anticipated to grow at a CAGR of 41% during the forecast period 2021-2030.
Cancer remains a significant global cause of mortality, claiming an estimated 0.6 million lives in the US alone in 2020. The World Health Organization foresees a staggering 70% surge in new cancer cases worldwide over the next two decades. Conventional treatments like chemotherapy, radiation therapy, and surgery, while commonly used, display limited efficacy, especially in advanced cancer stages. Moreover, their non-specific and highly toxic nature significantly compromises patients’ quality of life.
Emerging targeted anti-cancer therapies, particularly immunotherapy, have garnered attention for their ability to selectively target and eliminate tumor cells. Immunotherapeutic products, exemplified by immune checkpoint inhibitors such as atezolizumab, nivolumab, and pembrolizumab, demonstrate promising advantages with favorable side effect profiles, offering long-term clinical benefits to individuals with metastatic tumors. Innovative immunotherapies like dendritic cell therapy, T cell receptor transduced T cells, and chimeric antigen receptor (CAR)-modified T cells also hold potential in eradicating primary and metastatic cancer cells. However, these therapies entail risks, including severe and life-threatening side effects like cytokine storms. Additionally, T-cell therapies might result in detrimental biological effects due to mispairing of endogenous and transfected TCR ? and ? chains.
Cytokines have historically been explored in clinical trials as anti-cancer agents. Nevertheless, their systemic administration presents a range of dose-dependent side effects and unfavorable pharmacokinetic properties, limiting therapeutic dose escalation. To overcome these limitations, researchers are directing their attention toward immunocytokines—engineered fusion proteins that combine antibody target specificity with the immunological response capabilities of specific cytokines. These refined molecules exhibit enhanced efficacy and reduced toxicity compared to conventional cytokine-based therapies. Consequently, immunocytokines are under investigation for treating various conditions, including cancers, autoimmune disorders, and chronic inflammatory diseases. Notably, these emerging molecules display synergistic effects when combined with established therapeutics such as small molecule drugs (doxorubicin and cytarabine), intact antibodies (atezolizumab, durvalumab, ipilimumab, and nivolumab), radiation therapy, and other immunocytokines.
Encouraged by promising clinical trial outcomes, this burgeoning domain is expected to witness substantial market growth. Pioneers in this field are poised to benefit from being the first to introduce these advancements to market.
Report Coverage
Cancer remains a significant global cause of mortality, claiming an estimated 0.6 million lives in the US alone in 2020. The World Health Organization foresees a staggering 70% surge in new cancer cases worldwide over the next two decades. Conventional treatments like chemotherapy, radiation therapy, and surgery, while commonly used, display limited efficacy, especially in advanced cancer stages. Moreover, their non-specific and highly toxic nature significantly compromises patients’ quality of life.
Emerging targeted anti-cancer therapies, particularly immunotherapy, have garnered attention for their ability to selectively target and eliminate tumor cells. Immunotherapeutic products, exemplified by immune checkpoint inhibitors such as atezolizumab, nivolumab, and pembrolizumab, demonstrate promising advantages with favorable side effect profiles, offering long-term clinical benefits to individuals with metastatic tumors. Innovative immunotherapies like dendritic cell therapy, T cell receptor transduced T cells, and chimeric antigen receptor (CAR)-modified T cells also hold potential in eradicating primary and metastatic cancer cells. However, these therapies entail risks, including severe and life-threatening side effects like cytokine storms. Additionally, T-cell therapies might result in detrimental biological effects due to mispairing of endogenous and transfected TCR ? and ? chains.
Cytokines have historically been explored in clinical trials as anti-cancer agents. Nevertheless, their systemic administration presents a range of dose-dependent side effects and unfavorable pharmacokinetic properties, limiting therapeutic dose escalation. To overcome these limitations, researchers are directing their attention toward immunocytokines—engineered fusion proteins that combine antibody target specificity with the immunological response capabilities of specific cytokines. These refined molecules exhibit enhanced efficacy and reduced toxicity compared to conventional cytokine-based therapies. Consequently, immunocytokines are under investigation for treating various conditions, including cancers, autoimmune disorders, and chronic inflammatory diseases. Notably, these emerging molecules display synergistic effects when combined with established therapeutics such as small molecule drugs (doxorubicin and cytarabine), intact antibodies (atezolizumab, durvalumab, ipilimumab, and nivolumab), radiation therapy, and other immunocytokines.
Encouraged by promising clinical trial outcomes, this burgeoning domain is expected to witness substantial market growth. Pioneers in this field are poised to benefit from being the first to introduce these advancements to market.
Report Coverage
- The report thoroughly examines the immunocytokines market, analyzing target indications, administration routes, and major geographical regions. It delves into market drivers, restraints, opportunities, and challenges impacting growth. Moreover, it evaluates both advantages and obstacles within the market landscape, providing insights into the competitive environment for top players. Revenue forecasts for market segments across different countries are included.
- An in-depth analysis of the current market landscape concerning immunocytokines entails a comprehensive review from developmental phases of lead candidates, spanning discovery/preclinical stages to phase III trials. This evaluation categorizes therapy types—monotherapy and combination therapy—highlighting cytokine types (IL, IFN, TGF-?, TNF, and others) and antibody types (anti-CD20, anti-CEA, anti-CTLA-4, etc.). It also covers target disease indications, encompassing various categories like blood cancer, brain cancer, breast cancer, and more. Additionally, it considers the route of administration, including intravenous, intratumoral, subcutaneous, and other modes.
- The report features detailed profiles of leading immunocytokine developers in a tabulated format, summarizing company details, financial data, product portfolios, recent advancements, and future assessments. It analyzes recent market developments, such as partnerships, clinical trials, licensing, mergers, acquisitions, and research collaborations. Moreover, it examines investments across developmental stages in companies focused on immunocytokine research.
- A comprehensive review of completed, ongoing, and planned clinical studies of various immunocytokines considers parameters like trial registration year, development phase, patient population, study design, leading industry players, study focus, disease indications, and geographical regions.
- Furthermore, the report compiles key opinion leaders (KOLs) within the immunocytokine market, evaluating their expertise based on involvement in clinical studies. This assessment considers their publications, citations, trial participation, affiliations, and professional network strength, utilizing data sources including platforms like LinkedIn.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Cytokines
3.2.1. Engineered Cytokines and Immunocytokines
3.3. Challenges Associated with the Development of Immunocytokines
3.4. Future Perspectives
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Immunocytokines: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Therapy
4.2.3. Analysis by Type of Cytokine Used
4.2.4. Analysis by Type of Antibody Used
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Phase of Development, Type of Therapy, and Type of Cytokine Used
4.3. Immunocytokines: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Therapies
4.3.4. Regional Analysis of Therapy Developers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Genopharm
5.2.1. Company Overview
5.2.2. Immunocytokines Portfolio
5.2.2.1. GNP101
5.2.2.2. GNP201
5.2.2.3. GNP301
5.2.3. Recent Developments and Future Outlook
5.3. ImmunGene
5.3.1. Company Overview
5.3.2. Immunocytokines Portfolio
5.3.2.1. IGN001
5.3.2.2. IGN003
5.3.2.3. IGN004
5.3.2.4. IGN005
5.3.2.5. IGN006
5.3.3. Recent Developments and Future Outlook
5.4. Kanaph Therapeutics
5.4.1. Company Overview
5.4.2. Immunocytokines Portfolio
5.4.2.1. KNP-101
5.4.2.2. KNP-102
5.4.2.3. Cytokine X-Anti-Target A
5.4.2.4. Cytokine X-Anti-Target B
5.4.3. Recent Developments and Future Outlook
5.5. Merck KGaA
5.5.1. Company Overview
5.5.2. Immunocytokines Portfolio
5.5.2.1. EMD 521873
5.5.2.2. M7824
5.5.2.3. M9241
5.5.3. Recent Developments and Future Outlook
5.6. Philogen
5.6.1. Company Overview
5.6.2. Immunocytokines Portfolio
5.6.2.1. Daromun
5.6.2.2. F8IL10
5.6.2.3. F16IL2
5.6.2.4. IL12-L19L19
5.6.2.5. L19IL2
5.6.2.6. L19TNF
5.6.3. Recent Developments and Future Outlook
6. RECENT DEVELOPMENTS
6.1. Chapter Overview
6.2. Recent Developments: Partnerships and Collaborations
6.3. List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Most Active Players: Analysis by Number of Partnerships
6.3.5. Regional Analysis
6.3.5.1. Intercontinental and Intracontinental Agreements
6.4. Recent Developments: Types of Funding
6.5. Funding and Investment Analysis
6.5.1. Analysis by Number of Funding Instances (Cumulative), 2016-2020
6.5.2. Analysis by Amount Invested
6.5.3. Analysis by Type of Funding
6.5.4. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
6.5.5. Investment Summary by Region
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Immunocytokines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Trial Phase and Target Disease Indication
7.3.10. Geographical Analysis by Number of Clinical Trials
7.3.11. Geographical Analysis by Number of Patients Enrolled
8. KEY OPINION LEADERS (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs
8.4. Prominent KOLs
8.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Maastricht University)
8.6.2. KOL Profile: B (Centre Lйon Bйrard)
8.6.3. KOL Profile: C (Eberhard Karls University)
8.6.4. KOL Profile: D (Istituto Clinico Humanitas)
8.6.5. KOL Profile: E (Washington University in St. Louis)
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Immunocytokines Market, 2021-2030
9.4. Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication
9.4.1. Immunocytokines Market for Cervical Cancer, 2021-2030
9.4.2. Immunocytokines Market for Cholangiocarcinoma, 2021-2030
9.4.3. Immunocytokines Market for Esophageal Cancer, 2021-2030
9.4.4. Immunocytokines Market for Gallbladder Cancer, 2021-2030
9.4.5. Immunocytokines Market for Head and Neck Cancer, 2021-2030
9.4.6. Immunocytokines Market for Melanoma, 2021-2030
9.4.7. Immunocytokines Market for Non-small Cell Lung Cancer, 2021-2030
9.4.8. Immunocytokines Market for Rheumatoid Arthritis, 2021-2030
9.4.9. Immunocytokines Market for Soft Tissue Sarcoma, 2021-2030
9.5. Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration
9.5.1. Immunocytokines Market for Products Requiring Intravenous Administration, 2021-2030
9.5.2. Immunocytokines Market for Products Requiring Intratumoral Administration, 2021-2030
9.5.3. Immunocytokines Market for Products Requiring Subcutaneous Administration, 2021-2030
9.6. Global Immunocytokines Market, 2021 and 2030: Distribution by Geography
9.6.1. Immunocytokines Market in the US, 2021-2030
9.6.2. Immunocytokines Market in Canada, 2021-2030
9.6.3. Immunocytokines Market in Germany, 2021-2030
9.6.4. Immunocytokines Market in the UK, 2021-2030
9.6.5. Immunocytokines Market in France, 2021-2030
9.6.6. Immunocytokines Market in Italy, 2021-2030
9.6.7. Immunocytokines Market in Spain, 2021-2030
9.6.8. Immunocytokines Market in China, 2021-2030
9.6.9. Immunocytokines Market in Japan, 2021-2030
9.6.10. Immunocytokines Market in South Korea, 2021-2030
9.6.11. Immunocytokines Market in Australia, 2021-2030
9.6.12. Immunocytokines Market in Brazil, 2021-2030
9.6.13. Immunocytokines Market in Argentina, 2021-2030
9.6.14. Immunocytokines Market in Turkey, 2021-2030
9.6.15. Immunocytokines Market in Israel, 2021-2030
9.7. Immunocytokines Market, 2021-2030: Product-wise Sales Forecasts
9.7.1. Daromun
9.7.1.1. Target Patient Population
9.7.1.2. Sales Forecast
9.7.2. F8IL10
9.7.2.1. Target Patient Population
9.7.2.2. Sales Forecast
9.7.3. hu14.18-IL2
9.7.3.1. Target Patient Population
9.7.3.2. Sales Forecast
9.7.4. L19IL2
9.7.4.1. Target Patient Population
9.7.4.2. Sales Forecast
9.7.5. L19TNF
9.7.5.1. Target Patient Population
9.7.5.2. Sales Forecast
9.7.6. M7824
9.7.6.1. Target Patient Population
9.7.6.2. Sales Forecast
9.7.7. RO6874281
9.7.7.1. Target Patient Population
9.7.7.2. Sales Forecast
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Provenance Biopharmaceuticals
10.2.1. Company Snapshot
10.2.2. Interview Transcript: Stephen Gillies, President and Chief Executive Officer
10.3. Glycotope
10.3.1. Company Snapshot
10.3.2. Interview Transcript: Patrik Kehler, Senior Director Scientific and Business Development
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Cytokines
3.2.1. Engineered Cytokines and Immunocytokines
3.3. Challenges Associated with the Development of Immunocytokines
3.4. Future Perspectives
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Immunocytokines: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Therapy
4.2.3. Analysis by Type of Cytokine Used
4.2.4. Analysis by Type of Antibody Used
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Phase of Development, Type of Therapy, and Type of Cytokine Used
4.3. Immunocytokines: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Therapies
4.3.4. Regional Analysis of Therapy Developers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Genopharm
5.2.1. Company Overview
5.2.2. Immunocytokines Portfolio
5.2.2.1. GNP101
5.2.2.2. GNP201
5.2.2.3. GNP301
5.2.3. Recent Developments and Future Outlook
5.3. ImmunGene
5.3.1. Company Overview
5.3.2. Immunocytokines Portfolio
5.3.2.1. IGN001
5.3.2.2. IGN003
5.3.2.3. IGN004
5.3.2.4. IGN005
5.3.2.5. IGN006
5.3.3. Recent Developments and Future Outlook
5.4. Kanaph Therapeutics
5.4.1. Company Overview
5.4.2. Immunocytokines Portfolio
5.4.2.1. KNP-101
5.4.2.2. KNP-102
5.4.2.3. Cytokine X-Anti-Target A
5.4.2.4. Cytokine X-Anti-Target B
5.4.3. Recent Developments and Future Outlook
5.5. Merck KGaA
5.5.1. Company Overview
5.5.2. Immunocytokines Portfolio
5.5.2.1. EMD 521873
5.5.2.2. M7824
5.5.2.3. M9241
5.5.3. Recent Developments and Future Outlook
5.6. Philogen
5.6.1. Company Overview
5.6.2. Immunocytokines Portfolio
5.6.2.1. Daromun
5.6.2.2. F8IL10
5.6.2.3. F16IL2
5.6.2.4. IL12-L19L19
5.6.2.5. L19IL2
5.6.2.6. L19TNF
5.6.3. Recent Developments and Future Outlook
6. RECENT DEVELOPMENTS
6.1. Chapter Overview
6.2. Recent Developments: Partnerships and Collaborations
6.3. List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Most Active Players: Analysis by Number of Partnerships
6.3.5. Regional Analysis
6.3.5.1. Intercontinental and Intracontinental Agreements
6.4. Recent Developments: Types of Funding
6.5. Funding and Investment Analysis
6.5.1. Analysis by Number of Funding Instances (Cumulative), 2016-2020
6.5.2. Analysis by Amount Invested
6.5.3. Analysis by Type of Funding
6.5.4. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
6.5.5. Investment Summary by Region
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Immunocytokines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Trial Phase and Target Disease Indication
7.3.10. Geographical Analysis by Number of Clinical Trials
7.3.11. Geographical Analysis by Number of Patients Enrolled
8. KEY OPINION LEADERS (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs
8.4. Prominent KOLs
8.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Maastricht University)
8.6.2. KOL Profile: B (Centre Lйon Bйrard)
8.6.3. KOL Profile: C (Eberhard Karls University)
8.6.4. KOL Profile: D (Istituto Clinico Humanitas)
8.6.5. KOL Profile: E (Washington University in St. Louis)
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Immunocytokines Market, 2021-2030
9.4. Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication
9.4.1. Immunocytokines Market for Cervical Cancer, 2021-2030
9.4.2. Immunocytokines Market for Cholangiocarcinoma, 2021-2030
9.4.3. Immunocytokines Market for Esophageal Cancer, 2021-2030
9.4.4. Immunocytokines Market for Gallbladder Cancer, 2021-2030
9.4.5. Immunocytokines Market for Head and Neck Cancer, 2021-2030
9.4.6. Immunocytokines Market for Melanoma, 2021-2030
9.4.7. Immunocytokines Market for Non-small Cell Lung Cancer, 2021-2030
9.4.8. Immunocytokines Market for Rheumatoid Arthritis, 2021-2030
9.4.9. Immunocytokines Market for Soft Tissue Sarcoma, 2021-2030
9.5. Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration
9.5.1. Immunocytokines Market for Products Requiring Intravenous Administration, 2021-2030
9.5.2. Immunocytokines Market for Products Requiring Intratumoral Administration, 2021-2030
9.5.3. Immunocytokines Market for Products Requiring Subcutaneous Administration, 2021-2030
9.6. Global Immunocytokines Market, 2021 and 2030: Distribution by Geography
9.6.1. Immunocytokines Market in the US, 2021-2030
9.6.2. Immunocytokines Market in Canada, 2021-2030
9.6.3. Immunocytokines Market in Germany, 2021-2030
9.6.4. Immunocytokines Market in the UK, 2021-2030
9.6.5. Immunocytokines Market in France, 2021-2030
9.6.6. Immunocytokines Market in Italy, 2021-2030
9.6.7. Immunocytokines Market in Spain, 2021-2030
9.6.8. Immunocytokines Market in China, 2021-2030
9.6.9. Immunocytokines Market in Japan, 2021-2030
9.6.10. Immunocytokines Market in South Korea, 2021-2030
9.6.11. Immunocytokines Market in Australia, 2021-2030
9.6.12. Immunocytokines Market in Brazil, 2021-2030
9.6.13. Immunocytokines Market in Argentina, 2021-2030
9.6.14. Immunocytokines Market in Turkey, 2021-2030
9.6.15. Immunocytokines Market in Israel, 2021-2030
9.7. Immunocytokines Market, 2021-2030: Product-wise Sales Forecasts
9.7.1. Daromun
9.7.1.1. Target Patient Population
9.7.1.2. Sales Forecast
9.7.2. F8IL10
9.7.2.1. Target Patient Population
9.7.2.2. Sales Forecast
9.7.3. hu14.18-IL2
9.7.3.1. Target Patient Population
9.7.3.2. Sales Forecast
9.7.4. L19IL2
9.7.4.1. Target Patient Population
9.7.4.2. Sales Forecast
9.7.5. L19TNF
9.7.5.1. Target Patient Population
9.7.5.2. Sales Forecast
9.7.6. M7824
9.7.6.1. Target Patient Population
9.7.6.2. Sales Forecast
9.7.7. RO6874281
9.7.7.1. Target Patient Population
9.7.7.2. Sales Forecast
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Provenance Biopharmaceuticals
10.2.1. Company Snapshot
10.2.2. Interview Transcript: Stephen Gillies, President and Chief Executive Officer
10.3. Glycotope
10.3.1. Company Snapshot
10.3.2. Interview Transcript: Patrik Kehler, Senior Director Scientific and Business Development
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
